Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 5:25 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 2,431 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Esrd Clear all
Completed Early Phase 1 Interventional

Effects of Vitamin D Replacement on Hormones Regulating Iron Metabolism in Individuals With Chronic Kidney Disease

NCT01988116
View directory record Official record
Conditions
Chronic Kidney Disease, Anemia of Chronic Disease
Interventions
Oral Calcitriol 0.5 mcg once daily for 6 weeks, Placebo
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 24, 2015 · Synced Oct 27, 2026, 5:25 AM EDT
Recruiting Phase 2 Interventional

Sit Less, Interact and Move More (SLIMM) 2 Study

NCT05173714
View directory record Official record
Conditions
Chronic Kidney Diseases, Obesity
Interventions
SLIMM, Standard Resistance Training, Guided Resistance Training, Placebo, Semaglutide
Behavioral · Drug
Lead sponsor
Srinvasan Beddhu
Other
Eligibility
20 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
2
States / cities
Stanford, California • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 27, 2026, 5:25 AM EDT
Completed Not applicable Interventional

Argyle Safety Fistula Cannula With Anti-reflux Valve Clinical Study

NCT05927532
View directory record Official record
Conditions
End Stage Renal Failure on Dialysis
Interventions
Argyle Safety Fistula Cannula with Anti-Reflux Valve
Device
Lead sponsor
Mozarc Medical US LLC
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
3
States / cities
Hartford, Connecticut • Columbus, Georgia • Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Oct 27, 2026, 5:25 AM EDT
Completed Phase 2 Interventional Results available

Safety, Feasibility and Efficacy of Sulforaphane (Avmacol Extra Strength) in Chronic Kidney Disease

NCT05797506
View directory record Official record
Conditions
Chronic Kidney Disease Stage 3, Chronic Kidney Disease Stage 4
Interventions
Sulforaphane (Avmacol Extra Strength), Placebo
Drug · Dietary Supplement
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 80 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 27, 2026, 5:25 AM EDT
Completed Phase 2 Interventional Results available

Study of the Safety, Tolerability, and Pharmacokinetics of LHW090 in Patients With Moderately Impaired Renal Function

NCT02678000
View directory record Official record
Conditions
Chronic Kidney Disease (CKD)
Interventions
LHW090, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years to 85 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
7
States / cities
Anaheim, California • Lakewood, Colorado • Miami Lakes, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2021 · Synced Oct 27, 2026, 5:25 AM EDT
Completed Phase 4 Interventional Results available

Patiromer With or Without Food for the Treatment of Hyperkalemia

NCT02694744
View directory record Official record
Conditions
Hyperkalemia
Interventions
patiromer
Drug
Lead sponsor
Relypsa, Inc.
Industry
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
29
States / cities
Fountain Valley, California • Huntington Beach, California • Palm Springs, California + 21 more
Source: ClinicalTrials.gov public record
Updated May 12, 2021 · Synced Oct 27, 2026, 5:25 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Testing Educational Videos on Conservative Kidney Management

NCT06577571
View directory record Official record
Conditions
Kidney Disease, Chronic
Interventions
CKM-EMPOWER
Other
Lead sponsor
University of Washington
Other
Eligibility
Not listed
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 30, 2025 · Synced Oct 27, 2026, 5:25 AM EDT
Completed No phase listed Observational

Evaluation of the Risk of NSF Following ProHance Injection in Patients With Chronic Kidney Disease

NCT00600834
View directory record Official record
Conditions
Renal Insufficiency
Interventions
Not listed
Lead sponsor
Bracco Diagnostics, Inc
Industry
Eligibility
Not listed
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 4, 2014 · Synced Oct 27, 2026, 5:25 AM EDT
Recruiting Phase 1Phase 2 Interventional

Delayed Tolerance Through Mixed Chimerism

NCT05900401
View directory record Official record
Conditions
Kidney Failure, Kidney Transplant; Complications, Chimera
Interventions
Bone Marrow Transplant, Peripheral Blood Stem Cell Collection, Fludarabine, Cyclophosphamide, Rituximab, Siplizumab
Other · Procedure · Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 27, 2026, 5:25 AM EDT
Completed Not applicable Interventional

A Randomized Trial to Reduce the Disparity in Live Donor Kidney Transplantation

NCT00785265
View directory record Official record
Conditions
Chronic Kidney Disease, End-stage Renal Disease
Interventions
Group-Based (GB) Intervention, Home-Based (HB) Intervention
Behavioral
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
21 Years to 80 Years
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 10, 2020 · Synced Oct 27, 2026, 5:25 AM EDT
Completed Phase 3 Interventional Results available

Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for Treatment of Iron Deficiency Anemia in Non-Dialysis-Dependent Chronic Kidney Disease

NCT02940860
View directory record Official record
Conditions
Iron Deficiency Anaemia, Iron Deficiency Anemia, Chronic Kidney Disease
Interventions
Iron isomaltoside/ferric derisomaltose, Iron sucrose
Drug
Lead sponsor
Pharmacosmos A/S
Industry
Eligibility
18 Years and older
Enrollment
1,538 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
141
States / cities
Huntsville, Alabama • Little Rock, Arkansas • Chula Vista, California + 96 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2020 · Synced Oct 27, 2026, 5:25 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

To Compare the Pharmacokinetics of a Single Oral Dose of TC-5214 in Subjects With Renal Impairment and With Subjects With Normal Renal Function

NCT01240967
View directory record Official record
Conditions
Healthy Volunteers, Patients, Pharmacokinetics, Renal Impairment
Interventions
TC-5214
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
2
States / cities
Orlando, Florida • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 17, 2014 · Synced Oct 27, 2026, 5:25 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Pharmacokinetics Study of MBX 2109 in Adult Subjects With Normal and Impaired Renal Function

NCT06496217
View directory record Official record
Conditions
Renal Impairment
Interventions
MBX 2109
Drug
Lead sponsor
MBX Biosciences
Industry
Eligibility
18 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
3
States / cities
Miami, Florida • Tampa, Florida • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Oct 27, 2026, 5:25 AM EDT
Completed Phase 4 Interventional

Reference Group Trial for The ONE Study

NCT01656135
View directory record Official record
Conditions
End-stage Renal Failure, Kidney Graft Rejection
Interventions
Blood drawing for immune monitoring and questionnaires
Other
Lead sponsor
University of Regensburg
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
2
States / cities
San Francisco, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 9, 2016 · Synced Oct 27, 2026, 5:25 AM EDT
Completed Not applicable Interventional Results available

Cook Enforcer Post-Market Study

NCT03552289
View directory record Official record
Conditions
End-Stage Renal Disease
Interventions
Cook Advance® Enforcer 35 Focal-Force Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter, Conventional angioplasty balloon catheters
Device
Lead sponsor
Cook Research Incorporated
Industry
Eligibility
18 Years and older
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
5
States / cities
Phoenix, Arizona • Darien, Connecticut • Newark, Delaware + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Oct 27, 2026, 5:25 AM EDT
Completed Phase 2Phase 3 Interventional

Frequent Hemodialysis Network: Daily Trial

NCT00264758
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Conventional hemodialysis, Frequent hemodialysis
Device
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
13 Years and older
Enrollment
245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
2
States / cities
San Francisco, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 3, 2014 · Synced Oct 27, 2026, 5:25 AM EDT
Completed No phase listed Observational

Registry for HF20 for Pediatric CRRT Under Emergency Use Authorization

NCT04836026
View directory record Official record
Conditions
Pediatric Kidney Disease, Acute Kidney Injury
Interventions
HF20™
Device
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
3
States / cities
Palo Alto, California • Cincinnati, Ohio • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 21, 2023 · Synced Oct 27, 2026, 5:25 AM EDT
Terminated Phase 2 Interventional

Induction of Donor Specific Tolerance in Recipients of Living Kidney Allografts by Donor FCRx Infusion

NCT00497926
View directory record Official record
Conditions
Kidney Failure
Interventions
Enriched Hematopoietic Stem Cell Infusion
Biological
Lead sponsor
Talaris Therapeutics Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2023
U.S. locations
2
States / cities
Chicago, Illinois • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 11, 2023 · Synced Oct 27, 2026, 5:25 AM EDT
Enrolling by invitation No phase listed Observational

Assessment of Worldwide Acute Kidney Injury Epidemiology in Neonates 2.0

NCT06823115
View directory record Official record
Conditions
Acute Kidney Injury, Fluid Overload, Prematurity Complications, Risk Factors, Epidemiology, Chronic Kidney Disease(CKD), Hypertension
Interventions
Not listed
Lead sponsor
Indiana University
Other
Eligibility
0 Minutes to 2 Weeks
Enrollment
4,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
50
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Palo Alto, California + 45 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 27, 2026, 5:25 AM EDT
Completed No phase listed Observational

The CASABLANCA Study: Catheter Sampled Blood Archive in Cardiovascular Diseases

NCT00842868
View directory record Official record
Conditions
Atherosclerosis, Contrast Induced Nephropathy, Renal Impairment
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
1,298 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 19, 2016 · Synced Oct 27, 2026, 5:25 AM EDT
Active, not recruiting Not applicable Interventional

An Early Real-Time Electronic Health Record Risk Algorithm for the Prevention and Treatment of Acute Kidney Injury

NCT03590028
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
Early Nephrology Consult (ENC), Standard of Care (SOC)
Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 27, 2026, 5:25 AM EDT
Completed Phase 3 Interventional Results available

The BASE Study: Bicarbonate Administration to Stabilize Estimated Glomerular Filtration Rate (eGFR)

NCT02521181
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Lower Dose Sodium Bicarbonate, Higher Dose Sodium Bicarbonate, Placebo
Drug
Lead sponsor
Jennifer Gassman, PhD
Other
Eligibility
18 Years and older
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
7
States / cities
Denver, Colorado • Washington D.C., District of Columbia • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2020 · Synced Oct 27, 2026, 5:25 AM EDT
Terminated Phase 3 Interventional Results available

Study of the Effect of SZC on Serum Potassium and Serum Bicarbonate in Patients With Hyperkalemia and Metabolic Acidosis Associated With Chronic Kidney Disease

NCT04727528
View directory record Official record
Conditions
Hyperkalaemia, Metabolic Acidosis, Chronic Kidney Disease
Interventions
Sodium zirconium cyclosilicate, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
29
States / cities
Florence, Alabama • Chula Vista, California • Downey, California + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2023 · Synced Oct 27, 2026, 5:25 AM EDT
Completed Phase 3 Interventional Results available

A Two-Part, Single-Blind, Phase 3 Study Evaluating the Efficacy and Safety of Patiromer for the Treatment of Hyperkalemia (OPAL)

NCT01810939
View directory record Official record
Conditions
Chronic Kidney Disease (CKD), Hyperkalemia (HK)
Interventions
Patiromer, Placebo
Drug
Lead sponsor
Relypsa, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
243 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
14
States / cities
Azusa, California • Los Angeles, California • Sacramento, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2021 · Synced Oct 27, 2026, 5:25 AM EDT